Could a seawater balm soothe eczema as well as the gold standard?

NCT ID NCT07358000

Not yet recruiting Symptom relief Sponsor: University Hospital, Caen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new emollient balm made from seawater (Relipid+) to a leading balm (Lipikar) for mild to moderate eczema in people aged 6 months to 70 years. The goal is to see if the new balm works just as well at reducing symptoms and improving skin health. Researchers will also check if it helps the skin's microbiome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relipid+ balm (Active Oligo Skin from seawater)
What this could lead to: If it works, this could offer a more affordable, effective emollient option for managing eczema symptoms.
What could go wrong: This is a small, early-stage trial (86 people) comparing two balms, not a cure. The new balm may not be as effective as the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS EMOLLIENTS

Contacts and locations

Show contact details

Locations

CHU Caen Normandie

Caen, Normandy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.